Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002725468 | SCV002993889 | uncertain significance | RFT1-congenital disorder of glycosylation | 2021-08-14 | criteria provided, single submitter | clinical testing | This sequence change replaces threonine with isoleucine at codon 392 of the RFT1 protein (p.Thr392Ile). The threonine residue is moderately conserved and there is a moderate physicochemical difference between threonine and isoleucine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals affected with RFT1-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004673706 | SCV005162782 | uncertain significance | Inborn genetic diseases | 2024-03-18 | criteria provided, single submitter | clinical testing | The c.1175C>T (p.T392I) alteration is located in exon 11 (coding exon 11) of the RFT1 gene. This alteration results from a C to T substitution at nucleotide position 1175, causing the threonine (T) at amino acid position 392 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |